Honeybear Biosciences WIN~ WIN~ WIN~ Named a 2026 Hi-Po Star, Demonstrating Global Potential with Innovative ADC/ARC Technologies
Honeybear Biosciences has achieved another major milestone! Leveraging its innovative capabilities in the development of Antibody-Drug Conjugates (ADCs) and next-generation Antibody-Radionuclide Conjugates (ARCs), the company has distinguished itself among numerous startups and has been selected as a 2026 Hi-Po Star by the Small and Medium Enterprise and Startup Administration, Ministry of Economic Affairs (SMESA). The recognition highlights Honeybear Biosciences’ strong potential in technological innovation, R&D strategy, and future market development, positioning the company as a promising rising star in the biotech industry.
The Hi-Po Star Selection Program aims to identify innovative startups with high growth potential. In 2026, a total of 261 companies applied for the program. Following a rigorous two-stage selection process involving representatives from industry, venture capital, and the media, only 23 companies were ultimately selected. With its forward-looking technologies in biotechnology and healthcare, together with a clear international development strategy, Honeybear Biosciences stood out from the competition and earned recognition from the judging panel as one of this year’s most promising startups.
Honeybear Biosciences focuses on antibody-related technology platforms and innovative oncology drug development, with its core competitive advantage built around the CoNectar® high-specificity glyco-bonding technology platform, supported by a multi-country patent portfolio. Through precision glyco-bonding technology, the company aims to enhance the homogeneity and development flexibility of antibody-drug conjugates while actively expanding its applications in next-generation cancer therapeutics, including ADCs and ARCs. The company is also advancing its drug candidate development programs and actively connecting with academic, research, and industry partners in Taiwan and overseas to accelerate the translation of its innovative technologies toward clinical development and global markets.
Being selected as a Hi-Po Star not only recognizes Honeybear Biosciences’ R&D achievements and team capabilities, but also signifies growing recognition from the government and industry of the company’s technological innovation and commercial potential. Looking ahead, Honeybear Biosciences will continue to uphold its core values of “Innovation, Integrity, and Responsibility,” deepen the development of the CoNectar® technology platform, and advance its ADC and ARC drug development programs. Through international collaborations and strategic partnerships, the company will continue to enhance the global visibility of Taiwan’s innovative biotech R&D and steadily advance toward its vision of becoming a globally competitive innovator in oncology drug development.
Honeybear Biosciences has achieved another major milestone! Leveraging its innovative capabilities in the development of Antibody-Drug Conjugates (ADCs) and next-generation Antibody-Radionuclide Conjugates (ARCs), the company has distinguished itself among numerous startups and has been selected as a 2026 Hi-Po Star by the Small and Medium Enterprise and Startup Administration, Ministry of Economic Affairs (SMESA). The recognition highlights Honeybear Biosciences’ strong potential in technological innovation, R&D strategy, and future market development, positioning the company as a promising rising star in the biotech industry.
The Hi-Po Star Selection Program aims to identify innovative startups with high growth potential. In 2026, a total of 261 companies applied for the program. Following a rigorous two-stage selection process involving representatives from industry, venture capital, and the media, only 23 companies were ultimately selected. With its forward-looking technologies in biotechnology and healthcare, together with a clear international development strategy, Honeybear Biosciences stood out from the competition and earned recognition from the judging panel as one of this year’s most promising startups.
Honeybear Biosciences focuses on antibody-related technology platforms and innovative oncology drug development, with its core competitive advantage built around the CoNectar® high-specificity glyco-bonding technology platform, supported by a multi-country patent portfolio. Through precision glyco-bonding technology, the company aims to enhance the homogeneity and development flexibility of antibody-drug conjugates while actively expanding its applications in next-generation cancer therapeutics, including ADCs and ARCs. The company is also advancing its drug candidate development programs and actively connecting with academic, research, and industry partners in Taiwan and overseas to accelerate the translation of its innovative technologies toward clinical development and global markets.
Being selected as a Hi-Po Star not only recognizes Honeybear Biosciences’ R&D achievements and team capabilities, but also signifies growing recognition from the government and industry of the company’s technological innovation and commercial potential. Looking ahead, Honeybear Biosciences will continue to uphold its core values of “Innovation, Integrity, and Responsibility,” deepen the development of the CoNectar® technology platform, and advance its ADC and ARC drug development programs. Through international collaborations and strategic partnerships, the company will continue to enhance the global visibility of Taiwan’s innovative biotech R&D and steadily advance toward its vision of becoming a globally competitive innovator in oncology drug development.
Simon Chuang, CEO of Honeybear Biosciences (Right) was representing the company to accept the recognition of “2026 Hi-Po Star” from Minister Ming-Hsin Kung (Left), Ministry of Economic Affairs.
